Dehydroepiandrosterone sulfate
![]() |
|
![]() |
|
Names | |
---|---|
IUPAC name
[(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
|
|
Other names
Prasterone sulfate
|
|
Identifiers | |
651-48-9 ![]() |
|
Abbreviations | DHEAS |
ChemSpider | 12074 ![]() |
Jmol 3D model | Interactive image |
PubChem | 12594 |
|
|
|
|
Properties | |
C19H28O5S | |
Molar mass | 368.49 g/mol |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
Dehydroepiandrosterone sulfate or DHEA-S is a metabolite of dehydroepiandrosterone (DHEA).
Contents
Synthesis
Dehydroepiandrosterone sulfate is produced by the addition of a sulfate group, catalyzed by the sulfotransferase enzymes SULT1A1 and SULT1E1, which also produce estrone sulfate from estrone. DHEA sulfate can also be back-converted to DHEA through the action of steroid sulfatase.
In the zona reticularis layer of the adrenal cortex, DHEA-sulfate is generated by SULT2A1.[1] This layer of the adrenal cortex is thought to be the primary source of serum DHEA-sulfate. DHEA sulfate levels decline as a person ages as the reticularis layer diminishes in size.
Use as biomarker
Dehydroepiandrosterone sulfate levels above 1890 micromol/L or 700-800 µg/dL are highly suggestive of adrenal dysfunction because DHEA-S is made exclusively by the adrenal glands.[2][3] Presence of DHEA-S is therefore used to rule out ovarian or testicular origin of excess androgen.
Therapeutic use
The Endocrine Society recommends against the therapeutic use of DHEA sulfate in both healthy women and those with adrenal insufficiency, as their role is not clear from studies performed so far.[4] The routine use of DHEAS and other androgens is discouraged in the treatment of women with low androgen levels due to hypopituitarism, adrenal insufficiency, menopause due to ovarian surgery, glucocorticoid use, or other conditions associated with low androgen levels; this is because there are limited data supporting improvement in signs and symptoms with therapy and no long-term studies of risk.[4]
In otherwise elderly women, in whom an age-related fall DHEA sulfate may be associated with menopausal symptoms and reduced libido, DHEA sulfate supplementation cannot currently be said to improve outcomes.[5]
Reference ranges
Tanner stage and average age | Lower limit | Upper limit | Unit | |
---|---|---|---|---|
Tanner stage I | >14 days | 16 | 96 | µg/dL |
Tanner stage II | 10.5 years | 22 | 184 | |
Tanner stage III | 11.6 years | <15 | 296 | |
Tanner stage IV | 12.3 years | 17 | 343 | |
Tanner stage V | 14.5 years | 44 | 332 | |
18–29 years | 44 | 332 | ||
30–39 years | 31 | 228 | ||
40–49 years | 18 | 244 | ||
50–59 years | <15 | 200 | ||
> or =60 years | <15 | 157 |
Tanner stage and average age | Lower limit | Upper limit | Unit | |
---|---|---|---|---|
Tanner stage I | >14 days | <15 | 120 | µg/dL |
Tanner stage II | 11.5 years | <15 | 333 | |
Tanner stage III | 13.6 years | <15 | 312 | |
Tanner stage IV | 15.1 years | 29 | 412 | |
Tanner stage V | 18.0 years | 89 | 457 | |
18–29 years | 89 | 457 | ||
30–39 years | 65 | 334 | ||
40–49 years | 48 | 244 | ||
50–59 years | 35 | 179 | ||
> or =60 years | 25 | 131 |
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
Receptor (ligands) |
|
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (blockers) |
|
||||||||||||||||||||||||||||||
Enzyme (inhibitors) |
|
||||||||||||||||||||||||||||||
Others |
|
||||||||||||||||||||||||||||||
Receptor (ligands) |
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (blockers) |
|
||||||||||||||||||||||
Enzyme (inhibitors) |
|
||||||||||||||||||||||
Others | |||||||||||||||||||||||
Receptor (ligands) |
|
||||
---|---|---|---|---|---|
Transporter (blockers) |
|
||||
Others |
|
||||
Receptor (ligands) |
|
||||||||
---|---|---|---|---|---|---|---|---|---|
Enzyme |
|
||||||||
Others |
|
||||||||
Receptor (ligands) |
|
||||||||
---|---|---|---|---|---|---|---|---|---|
Enzyme |
|
||||||||
Others |
|
||||||||
CAR |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ERR |
|
||||||||||||||||||||||||||
FXR |
|
||||||||||||||||||||||||||
LXR |
|
||||||||||||||||||||||||||
PPAR |
|
||||||||||||||||||||||||||
PXR |
|
||||||||||||||||||||||||||
RAR |
|
||||||||||||||||||||||||||
RXR |
|
||||||||||||||||||||||||||
SHR |
|
||||||||||||||||||||||||||
TR |
|
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 4.0 4.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 6.0 6.1 Dehydroepiandrosterone Sulfate (DHEA-S), Serum at Mayo Foundation For Medical Education And Research. Retrieved July 2012
- Pages with reference errors
- Articles without EBI source
- Articles without KEGG source
- Articles without UNII source
- Articles with changed InChI identifier
- Pages using collapsible list with both background and text-align in titlestyle
- Chemical articles using a fixed chemical formula
- Metabolism
- Human metabolites
- Neurosteroids
- Organosulfates
- Steroids
- GABAA receptor negative allosteric modulators
- Glycine receptor antagonists
- NMDA receptor agonists
- Pregnane X receptor agonists
- Sigma agonists